As cellular therapies are advancing through clinical development and getting closer to market, close collaborations between stem cell biologists, clinical cell processing technologists, and bioengineers will be required for effective commercializa
Modern recombinant DNA expression technologies, by definition, challenge cells to engage in unnatural acts; specifically, the production of new types and large quantities of proteins for which the cells have not evolved.
The drug discovery process is expensive and often inefficient. With the emergence of genomic and proteomic information, the growth of critical molecular targets is rapid.
Biotechnological processes depend to a large extent on the productivity of the organisms used.
